- Home
- BRAG vs AGEN Comparison
BRAG vs AGEN Comparison
Compare BRAG & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRAG
- AGEN
- Stock Information
- Founded
- BRAG 2018
- AGEN 1994
- Country
- BRAG Canada
- AGEN United States
- Employees
- BRAG N/A
- AGEN N/A
- Industry
- BRAG Office Equipment/Supplies/Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRAG Technology
- AGEN Health Care
- Exchange
- BRAG Nasdaq
- AGEN Nasdaq
- Market Cap
- BRAG 114.3M
- AGEN 96.2M
- IPO Year
- BRAG N/A
- AGEN 2000
- Fundamental
- Price
- BRAG $3.31
- AGEN $3.34
- Analyst Decision
- BRAG Buy
- AGEN Buy
- Analyst Count
- BRAG 2
- AGEN 3
- Target Price
- BRAG $7.50
- AGEN $9.33
- AVG Volume (30 Days)
- BRAG 81.6K
- AGEN 639.0K
- Earning Date
- BRAG 11-14-2024
- AGEN 11-12-2024
- Dividend Yield
- BRAG N/A
- AGEN N/A
- EPS Growth
- BRAG N/A
- AGEN N/A
- EPS
- BRAG N/A
- AGEN N/A
- Revenue
- BRAG $109,522,641.00
- AGEN $160,427,000.00
- Revenue This Year
- BRAG $10.73
- AGEN N/A
- Revenue Next Year
- BRAG $9.35
- AGEN $0.04
- P/E Ratio
- BRAG N/A
- AGEN N/A
- Revenue Growth
- BRAG 4.64
- AGEN 59.00
- 52 Week Low
- BRAG $2.86
- AGEN $2.50
- 52 Week High
- BRAG $7.00
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- BRAG 27.29
- AGEN 42.62
- Support Level
- BRAG $3.20
- AGEN $2.50
- Resistance Level
- BRAG $3.41
- AGEN $2.89
- Average True Range (ATR)
- BRAG 0.22
- AGEN 0.32
- MACD
- BRAG -0.09
- AGEN -0.01
- Stochastic Oscillator
- BRAG 25.86
- AGEN 43.75
About BRAG Bragg Gaming Group Inc.
Bragg Gaming Group Inc is predominantly a B2B online gaming technology platform and casino content aggregator. The Company's proprietary studios offer high-performing, data-driven casino gaming titles from in-house brands Wild Streak, Spin, Atomic Slot Lab, Indigo Magic and Oryx Gaming. It offers a full range of games including slot games, table games, card games, video bingo, scratch card games, virtual sports, and live dealer games which are featured on the company's PAM platform and also available for use on other gaming platforms offered by third parties. Geographically, the company generates a majority of its revenue from the Netherlands and the rest from Curacao, Malta, United States, Croatia, and other regions.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).